Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tesamorelin - Theratechnologies

Next Previous
Drug Profile

Tesamorelin - Theratechnologies

Alternative Names: EGRIFTA; EGRIFTA MDVTM; EGRIFTA SV; EGRIFTA WR; F4; F8; Tesamorelin acetate; TH-9507; ThGRF 1-44

Latest Information Update: 07 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Theratechnologies
  • Developer National Heart, Lung and Blood Institute; National Institute on Aging; Theratechnologies
  • Class Antidementias; Hepatoprotectants; Pituitary hormone releasing hormones; Sleep disorder therapies
  • Mechanism of Action Growth hormone releasing factor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Non-alcoholic steatohepatitis

Highest Development Phases

  • Marketed Lipodystrophy
  • Phase II Mild cognitive impairment; Non-alcoholic steatohepatitis
  • Discontinued Insomnia; Lipid metabolism disorders; Muscular atrophy

Most Recent Events

  • 25 Mar 2025 US FDA approves Tesamorelin for treatment of lipodystrophy in the US
  • 14 Feb 2025 Theratechnologies anticipates FDA approval of tesamorelin's Prior Approval Supplement by April 18, 2025
  • 10 Dec 2024 The US FDA sets PDUFA date of 25/03/2025 for sBLA review for F8 formulation of tesamorelin

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top